The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

Learn all about various types of certificates of deposit, how they work and how they potentially fit into your savings and investment planning. Browse Investopedia’s expert-written library to ...

Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity. Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity.

Certificates provide assurance to current and prospective employers that you have what it takes to get the job done. Gain recognition by getting your name listed in the ISA Credential Directory, used ...

Labour and Welfare (MHLW) has granted orphan drug designation to its drug setmelanotide for treating acquired hypothalamic obesity. According to InvestingPro data, the company maintains an ...

Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity. Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity.

Labour and Welfare (MHLW) has granted orphan drug designation to its drug setmelanotide for treating acquired hypothalamic obesity. According to InvestingPro data, the company maintains an exceptional ...

Arcturus Therapeutics Holdings Inc. (ARCT) reported a wider-than-expected loss for the fourth quarter of 2024, with earnings per share (EPS) of -$1.11, missing the forecast of -$0.19. The company ...

Catalyst Pharmaceuticals reported 2024 revenues of $491.7 million, projecting growth to $545-$565 million in 2025. Catalyst Pharmaceuticals, Inc. reported a record total revenue of $491.7 million ...

Our Online Certificate Courses provide the expert knowledge and skills you need to enhance your career. From leadership and management, to finance and economics, to technology, law and public policy, ...

CEL-SCI Corporation announced new data has been published from its prior Phase 3 study of Multikine* (Leukocyte Interleukin, Injection) in newly diagnosed, treatment naïve, resectable, locally ...